J&J secures expanded FDA approval for Tremfya to include ulcerative colitis
Tremfya is a dual-acting interleukin-23 inhibitor approved in active ulcerative colitis (UC) and showed highly statistically significant rates of endoscopic remission at one year in the Phase 2b/3 Quasar clinical trial
